The reset in Ginkgo Bioworks Holdings’ price target from US$9 to US$5 sits against an unchanged fair value estimate of US$8.67 per share, putting a sharper spotlight on how analysts are framing risk ...
Ginkgo Bioworks (DNA) plunged nearly 14% on Friday after outlining FY26 cash burn guidance in the range of $125M to $150M ...
MarketBeat on MSN
Ginkgo Bioworks Q1 earnings call highlights
Ginkgo Bioworks (NYSE:DNA) said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture ...
Ongoing drag from real estate and commitments was highlighted via lease and cloud items: "the carrying cost of excess lease space...$16 million" and the $14 million Google Cloud payment impacting Q1 ...
As of Friday, May 08, Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 13.95%, which has investors questioning ...
Find the latest Ginkgo Bioworks news from Fast company. See related business and technology articles, photos, slideshows and ...
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with ...
Ginkgo Bioworks Holdings, Inc. () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful inv ...
The cell programming upstart is partnering with behemoths like Pfizer and Alphabet. The business remains unproven, incurring heavy losses over the past four quarters. Plus, its cash burn could ...
Ginkgo Bioworks is a cell programming specialist that has partnered with many big companies. It is in a very early stage, but has a lot of promising opportunities in the long run. A big part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results